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For the past three decades of research, p53 has been
identified as one of the most targetable molecules for
developing anticancer treatments. This tumor suppressor
protein is involved in apoptosis, cell cycle arrest and
senescence. Impairment of p53 function in tumors occurs
either as a result of mutations in the TP53 gene itself or
the abrogation of signaling pathways regulating p53 that
are required to exert its cellular function [1]. MDM2 is a
transcriptional target of p53, which creates an important
negative feedback loop that controls the activity of p53 in
response to stress. The MDM2 E3 ubiquitin ligase tightly
regulates p53 by targeting it for ubiquitin-dependent pro-
teasomal degradation [2]. In experimental models, dis-
rupting the MDM2–p53 interaction restored p53
function and sensitized tumors to chemotherapy or
radiotherapy. This strategy could be particularly benefi-
cial in treating cancers that rarely harbor TP53 muta-
tions/deletions; for example, hematologic malignancies
such as multiple myeloma (MM), chronic lymphocytic
leukemia (CLL), acute lymphoblastic leukemia (ALL),
and acute myeloid leukemia (AML) [1,3].
The most well studied small-molecule inhibitor of the
MDM2–p53 complex is nutlin. Nutlins are a group of
cis-imidazoline analogs that have a high binding potency
and selectivity for MDM2 and are being tested in phase I
clinical trials in patients with hematologic neoplasms and
advanced solid tumors [4]. p53-mediated effects of nutlin,
such as induction of cell cycle arrest and/or apoptosis,
have been demonstrated in cancers characterized by non-
mutated TP53, including B-CLL, AML, and ALL [1].
Moreover, it can inhibit tumor growth in a non-geno-
toxic manner in xenografted tumor mice [1]. We have
provided the evidence that nutlin mediated apoptosis can
be mediated by both extrinsic and intrinsic pathways.
Importantly, our study demonstrated that nutlin can
utilize both p53-transcription-depepdent and transcrip-
tion-independent mechanisms to trigger p53-mediated
apoptosis suggesting that transcriptional and mitochon-
drial functions of p53 are equally important for nutlin-
triggered apoptosis in MM cells [5].
Another activator of the p53 pathway is the small
molecule RITA (reactivation of p53 and induction of
tumor cell apoptosis) which is not yet in clinical trials.
RITA acts differently to the nutlins by binding directly to
its proposed p53 (rather than MDM2) binding site and
blocking its ability to interact with MDM2 [6]. However,
there appears other mechanisms by which RITA
increases p53 activity in cells, since there is evidence that
RITA can bind to multiple proteins and activate DNA
damage response pathways [7]. We previously evaluated
anti-myeloma activity of RITA and showed that RITA-
induced apoptosis in MM cells is mediated by caspase-
dependent extrinsic pathways. On the other hand, non-
malignant cells seem to tolerate RITA and no significant
toxic effects have been observed in normal cells [8].
More recently, our study reveals that RITA induced
p53-dependent apoptosis of MM cells is mediated by tar-
geting JNK or its upstream targets. Both genetic and
pharmacological Inhibition of JNK activation resulted in
inhibition of activation of p53 and induction of apoptosis
by RITA [9]. Moreover, RITA shows preclinical activity
for retardation of tumor growth and prolongation of sur-
vival in MM mouse xenograft models. In addition, we
also demonstrated potential synergistic cytotoxic
responses of RITA in combination with nutlin [8] or with
the JNK activators dexamethasone or 2-Cyano-3,12-diox-
ooleana-1,9-dien-28 oic Acid (CDDO) [9]; or of nutlin in
combination with velcade, a proteasome inhibitor [10].
Our results indicated a novel mechanism for RITA in
JNK signaling and p53-mediated apoptosis in MM cells
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and provided a preclinical framework for evaluating RITA
in clinical trials for the treatment of MM.
Our studies underscore the tremendous potential of
these two small molecules for enhancing our understand-
ing of the intricate complexities between different net-
works of cell death as well as for therapeutic induction of
apoptosis in myeloma cells. Further, nutlin or RITA in
combination with other available therapeutic agents and
also as single agents present a promising novel approach
for p53-targeted therapies of MM, which warrants
further exploitation.
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